The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-driven cancers, and we sought to characterize the molecular determinants of response and resistance. We find that the pre-treatment genomic landscape does not shape the variability of treatment response except...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, Ezra Y., Won, Helen H., Zheng, Youyun, Cocco, Emiliano, Selcuklu, Duygu, Gong, Yixiao, Friedman, Noah D., de Bruijn, Ino, Sumer, Onur, Bielski, Craig M., Savin, Casey, Bourque, Caitlin, Falcon, Christina, Clarke, Nikeysha, Jing, Xiaohong, Meng, Fanli, Zimel, Catherine, Shifman, Sophie, Kittane, Srushti, Wu, Fan, Ladanyi, Marc, Ebata, Kevin, Kherani, Jennifer, Brandhuber, Barbara J., Fagin, James, Sherman, Eric J., Rekhtman, Natasha, Berger, Michael F., Scaltriti, Maurizio, Hyman, David M., Taylor, Barry S., Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933489/
https://www.ncbi.nlm.nih.gov/pubmed/35304457
http://dx.doi.org/10.1038/s41467-022-28848-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933489/
https://www.ncbi.nlm.nih.gov/pubmed/35304457
http://dx.doi.org/10.1038/s41467-022-28848-x

Ejemplares similares